Kolon TissueGene, Inc. (KOSDAQ:950160)

Kolon TissueGene Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	100,454	802.87	27,433	41,563	38,813	18,522
Short-Term Investments	17,522	-	-	16,700	200.03	37,808
Cash & Short-Term Investments	117,976	802.87	27,433	58,263	39,013	56,330
Cash Growth	310.73%	-97.07%	-52.92%	49.34%	-30.74%	-46.38%
Accounts Receivable	365.15	237.73	183.58	33.64	334.24	583.7
Other Receivables	330.68	25.84	1,195	700.99	8.56	154.6
Receivables	695.84	263.58	1,378	734.62	342.8	738.3
Inventory	39.3	93.46	64.28	16.56	170.58	341.6
Prepaid Expenses	2,032	1,435	1,283	1,252	1,536	1,557
Other Current Assets	8,340	4,821	1,872	2,804	2,386	4,047
Total Current Assets	129,084	7,415	32,031	63,070	43,449	63,014
Property, Plant & Equipment	6,367	6,971	7,061	8,157	8,945	9,132
Other Intangible Assets	139.18	182.12	126.01	234.49	202.97	277.6
Long-Term Deferred Charges	264,151	200,081	87,539	30,990	5,790	-
Other Long-Term Assets	7,232	7,639	8,154	7,439	3,013	348.45
Total Assets	406,972	222,288	134,910	109,890	61,399	72,839
Accounts Payable	552.44	325.38	253.51	102.69	90.35	259.6
Accrued Expenses	1,375	3,200	1,709	2,529	9,901	4,082
Short-Term Debt	70,711	10,894	-	-	-	5,440
Current Portion of Leases	1,177	1,072	907.64	800.14	654.92	686.98
Current Unearned Revenue	1.95	8.95	9	-	-	-
Other Current Liabilities	144,355	55,610	11,424	8,172	5,496	4,729
Total Current Liabilities	218,173	71,111	14,303	11,604	16,143	15,197
Long-Term Debt	-	-	-	-	-	2,720
Long-Term Leases	4,351	5,274	5,568	6,273	6,578	6,647
Pension & Post-Retirement Benefits	77.12	-	-	-	-	-
Other Long-Term Liabilities	0	0	75.75	524.12	31	166
Total Liabilities	222,601	76,384	19,947	18,401	22,752	24,730
Common Stock	2.33	2.34	1.88	1.75	1.54	1.33
Additional Paid-In Capital	673,815	587,429	470,458	424,164	339,585	279,117
Retained Earnings	-489,337	-441,532	-355,250	-332,401	-300,732	-230,843
Comprehensive Income & Other	-110.72	2.73	-248.43	-277.49	-208.79	-168.65
Total Common Equity	184,369	145,902	114,962	91,487	38,646	48,107
Shareholders' Equity	184,371	145,904	114,963	91,489	38,648	48,108
Total Liabilities & Equity	406,972	222,288	134,910	109,890	61,399	72,839
Total Debt	76,240	17,240	6,476	7,074	7,233	15,494
Net Cash (Debt)	41,736	-16,437	20,957	51,189	31,781	40,836
Net Cash Growth	252.19%	-	-59.06%	61.07%	-22.18%	-50.35%
Net Cash Per Share	512.90	-213.60	292.25	772.24	519.01	668.80
Filing Date Shares Outstanding	81.49	80.04	73.21	69.97	61.91	61.06
Total Common Shares Outstanding	81.49	80.04	73.21	69.97	61.91	61.06
Working Capital	-89,089	-63,695	17,727	51,466	27,306	47,817
Book Value Per Share	2262.57	1822.92	1570.27	1307.54	624.28	787.88
Tangible Book Value	184,230	145,720	114,836	91,253	38,443	47,829
Tangible Book Value Per Share	2260.86	1820.65	1568.55	1304.18	621.00	783.34
Machinery	1,450	1,035	910.56	965.54	276.33	857.11

Source: S&P Global Market Intelligence. Standard template. Financial Sources.